Business Context and Reporting Period
Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: ASHS provides turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy. Operations are divided into two segments: Leasing (medical equipment leasing to hospitals) and Retail (direct patient services at owned facilities).
Key Event: On May 7, 2024, the Company closed the acquisition of a 60% interest in the "RI Companies" (three radiation therapy centers in Rhode Island) from GenesisCare for $2.85 million.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | 2024 (6 Months) | 2023 (6 Months) |
|---|---|---|
| Total Revenue | $12,272,000 | $10,493,000 |
| Gross Margin | $4,611,000 (37.6%) | $4,426,000 (42.2%) |
| Operating Loss | $(86,000) | $(227,000) |
| Net Income (Total) | $3,833,000 | $(77,000) |
| Net Income Attributable to ASHS | $3,721,000 | $77,000 |
| Diluted EPS | $0.57 | $0.01 |
| Cash and Equivalents | $14,486,000 | $13,794,000 |
| Working Capital | $12,303,000 | $9,677,000 (Dec 31, 2023) |
| Total Debt (Long-term + Current) | $19,033,000 | $15,625,000 (Dec 31, 2023) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 17% year-over-year. The Retail segment grew 184% ($4.12M vs $1.45M) driven by the RI Acquisition and higher international volumes. The Leasing segment declined 10% ($8.15M vs $9.04M) due to lower Gamma Knife and PBRT volumes and expiring contracts.
- Profitability Surge: Net income turned from a loss of $77,000 in 2023 to $3.83 million in 2024. This is primarily attributable to a $3.679 million bargain purchase gain recognized from the RI Acquisition.
- Cost Structure: Total costs of revenue increased 26% to $7.66 million, driven by operating costs from the newly acquired RI facilities and higher depreciation on upgraded equipment.
- Balance Sheet: Total assets increased to $60.8 million from $48.2 million. Accounts receivable nearly doubled to $8.6 million, reflecting the inclusion of the RI Companies' receivables.
Guidance, Outlook, Risks, and Unusual Items
Unusual Items
- Bargain Purchase Gain: A non-recurring gain of $3.679 million was recorded due to the fair value of assets acquired in the RI Acquisition exceeding the purchase price. Excluding this gain, the company reported an operating loss of $86,000 for the six-month period.
Outlook and Commitments
- Capital Expenditures: The Company has commitments of $15.65 million to purchase and install five Gamma Knife Esprit systems and three LINAC systems. It intends to finance substantially all of these commitments.
- Service Commitments: Total service commitments for equipment maintenance are $14.375 million.
- Expansion: A new joint venture in Guadalajara, Mexico, is expected to begin treating patients in the first half of 2025.
Risks and Contingencies
- SEC Compliance Risk: The Company disclosed it is not in compliance with Rules 8-04 and 8-05 of Regulation S-X regarding the RI Acquisition. Due to the target's bankruptcy history, reliable historical financial statements could not be obtained. This non-compliance limits the Company's ability to file effective registration statements or sell securities under Rule 144 for 12 months following the filing of a compliant periodic report.
- Financing Risk: There is no assurance that financing will be available for future projects on acceptable terms.
- Reimbursement Risk: Potential implementation of the Radiation Oncology Alternative Payment Model (RO APM) by CMS could alter payment methodologies.
Investor Verification Checklist
- Quality of Earnings: Verify the sustainability of earnings by excluding the $3.679 million one-time bargain purchase gain, which masks an underlying operating loss.
- Regulatory Status: Confirm the impact of the Regulation S-X non-compliance on future capital raising activities and stock liquidity (Rule 144 restrictions).
- Debt Covenants: Review compliance with the Fifth Third Bank Credit Agreement (minimum fixed charge coverage ratio of 1.25 and debt-to-EBITDA of 3.0).
- Receivables Quality: Assess the collectability of the significant increase in accounts receivable ($8.6M), particularly from the newly acquired RI facilities and international operations.
- Financing Availability: Evaluate the Company's ability to secure the necessary financing for the $15.65 million in equipment commitments given current market conditions.